Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.

Shen Zhao,Rongbo Lin,Nanfeng Fan,Yigui Chen,Xiaofeng Li,Peicheng Lin,Wujin Chen,Wenzheng Fang,Jinfeng Zhu,Hui Li,Jie Liu

Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.

2021

Shen Zhao
Rongbo Lin
Nanfeng Fan
Yigui Chen
Xiaofeng Li
Peicheng Lin
Wujin Chen
Wenzheng Fang
Jinfeng Zhu
Hui Li
Jie Liu

4041Background: Progression-free (PFS) and overall (OS) survival for SYLT/FNF 004 were previously reported in ASCO and ASCO-GI 2019. At that time, PFS was statistically significantly improved with ...

Keywords:

Internal medicine
Paclitaxel
Medicine
FOLFOX
Oncology
advanced gastric cancer
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations